Track topics on Twitter Track topics that are important to you
The European Commission approved the expanded use of Novartis’ Zykadia ® (ceritinib) to include first-line treatment of advanced non-small cell lung cancer (NSCLC) in patients with anaplastic lymphoma kinase (ALK)-positive tumors . "Today's EC approval of Zykadia as a first-line treatment of ALK+ non-small cell lung cancer is an important stepforward for patients with this type of serious disease," said Bruno Strigini, CEO, Novartis Oncology. "Our commitment to innovation in lung cancer will continue and we look forward to providing additional advancements for patients as the incidence of the disease grows around the world." Last month FDA approved the ALK-inhibitor Zykadia as first-line therapy for ALK-positive NSCLC following confirnation by an FDA-approved test. Expanded use of Zykadia as first-line therapy for ALK-positive NSCLC in Europe and in the U.S., was based on data from the Phase III ASCEND-4 study in 376 previously untreated adult patients with stage ...
Original Article: EC Clears Expanded Use of Novartis' Zykadia for First Line NSCLS TherapyNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...